PRESS RELEASE: FOR MEDICAL AND TRADE PRESS
Issued: London, Tuesday 4th October 2022
Announced today, ALTURiX – a rapidly-growing British pharmaceutical company – has acquired the exclusive rights to desmopressin oral solution for the United Kingdom following the finalisation of an agreement with GP Pharm and REIG JOFRE, both based in Spain.
Commenting on the agreement, Simon Fisher, Founder and Director at ALTURiX said,
“We are very pleased to announce this deal with GP Pharm and REIG JOFRE for such an important product for UK patients. This agreement is the third recent example of our successful growth strategy in action, and once again shows the company’s commitment to reliably and affordably supply important products like desmopressin. We are delighted that we can help by increasing the currently-limited options available to prescribers, patients, their families, and the NHS.”
